The Peking University Health Cohort in Anning, Yunnan (PKUHC-AN) is a prospective cohort study carried out in Anning, Yunnan. The primary aim of this study is to investigate the impact of COVID-19 on older adults' health, and to provide high-quality evidence of real world research for the optimization of prevention and control strategies of COVID-19 and other emerging infectious diseases. Data will be collected regarding health status, history of COVID-19 infections and vaccines, lifestyle and socioeconomic characteristics, as well as the short- and long-term health outcomes.
COVID-19 pandemic attributed to a great number of mortalities around the world in the last 3 years. About 46% of the global population are estimated to have been infected by the omicron variant and its sublineages. Health outcomes post COVID-19 has been of great concern globally since more and more people infected by SARS-CoV-2. Integrated efforts should be made to estimate the incidence of reinfections and long COVID in China, especially among older adults who are vunlerable and susceptible to COVID-19. In view of this, the Peking University Health Cohort Study in Anning, Yunnan aims to investigate the impact of COVID-19 on older adults' health, and to provide high-quality evidence of real world research for the optimization of prevention and control strategies of COVID-19 and other emerging infectious diseases. Data will be collected regarding health status, history of COVID-19 infections and vaccines, lifestyle and socioeconomic characteristics, as well as the short- and long-term health outcomes.
Study Type
OBSERVATIONAL
Enrollment
11,527
This is an observational study without any intervention.
Anning medical community
Kunming, Yunan, China
Incidence of long COVID
The proportion of participants incurred any symptoms or diagnosed diseases of post-COVID in all infected participants.
Time frame: From baseline until the date of long COVID symptoms or date of death from any cause, whichever came first, assessed up to 12 months.
Reinfection incidence of COVID-19
The proportion of participants infected by COVID-19 at least 2 times. Measured by trained health professionals.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Cognitive impairment
Measured by health professionals using MMSE (Mini-Mental State Exam). The MMSE cognitive screening test is a 30-point questionnaire for analyzing several cognitive functions including memory, orientation, attention, calculation, and language. MMSE is measured on a scale between 0 and 30, where scores of 0-9, 10-20, 21-26, and 27-30 indicate severe, moderate, mild, and normal cognitive function, respectively.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Depression
Measured by health professionals using PHQ-9 (Patient Health Questionnaire-9). PHQ-9 provides a score ranging from 0 to 27, where scores of \<4, 5-9, 10-14, 15-19, and 20-27 represented no, mild, moderate, moderately severe, and severe depression, respectively.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Medical expenditure
Measured by health professionals using self-designed questionnaire about their past month outpatient expenditure and past year inpatient expenditure.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Incidence of catastrophic health expenditure
Measured by health professionals using self-designed questionnaire about their households' past year consumption expenditure (including food expenditure, cloths expenditure, transportation expenditure and so on), and calculated as the proportion of households whose out-of-pocket medical expenditure exceed 40% of household non-food expenditure.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
Sleep quality
Measured by health professionals using PSQI (Pittsburgh Sleep Quality Index). PSQI reflects sleep for a month, includes 18 items (7 subscales): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. The range of PSQI global score is 0-21, and a score of \>5 or 7 is indicative of poor sleep quality.
Time frame: At 3 months, 6 months, 9 months, 1 year after baseline investigation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.